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Abstract
Background To prospectively investigate patients with sea-
sonal allergic conjunctivitis (SAC) during the pollen season
and test associations between tears total IgE, eotaxin concen-
trations, and SAC severity.
Methods Enrolled patients presented ocular symptoms and
clinical signs of SAC at the time of presentation. Ocular
itching, hyperaemia, chemosis, eyelid swelling, and tearing
were scored, and the sum of these scores was defined as the
clinical score. Conjunctival papillae were separately graded.
We measured eotaxin concentration in tears by an enzyme-
linked immunosorbent assay (ELISA) and total tear IgE by
Lacrytest strip.
Results Among thirty patients (30 eyes), 11 showed neither
tear IgE nor tear eotaxin, while 15 out of 19 patients with
positive IgE values presented a positive amount of eotaxin in
their tears (Fisher’s test: p<0.001). The mean eotaxin concen-
tration was 641±154 (SEM) pg/ml. In patients with no
amount of tear IgE, we observed a lower conjunctival papilla
grade than in patients whose tears contained some amount of
IgE (trend test: p=0.032). In the 15 patients whose tear
eotaxin concentration was null, tear IgE concentration was
5.3±3.5 arbitrary units; in the other 15 patients whose eotaxin
was positive, IgE reached 21±4.3 arbitrary U (Mann–Whit-
ney: p<0.001). We measured 127±47 pg/ml eotaxin in pa-
tients with no history of SAC but newly diagnosed as suffer-
ing from SAC, and 852±218 pg/ml eotaxin in patients with a
known SAC (p=0.008). In contrast, tear IgE concentrations
of both groups did not differ statistically significantly
(p=0.947).
Conclusions If IgE and eotaxin secreted in tears are major
contributors in SAC pathogenesis, they however act at differ-
ent steps of the process.
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Introduction
Allergic diseases, such as asthma, dermatitis, food allergy, and
allergic conjunctivitis, affect one third of the population [1, 2].
These diseases have an important impact on patient quality of
life and comfort, and result in a burden on the economy
through healthcare costs and productivity reduction. Among
ocular allergies, seasonal allergic conjunctivitis (SAC) affects
a great number of patients. Understanding better the patho-
genesis of SAC could help in treating patients [3, 4].
Tear film plays an important role in maintaining a barrier
defence at the ocular surface. During SAC, specific Immuno-
globulin E (IgE) molecules are secreted in tears and combine
with Fc receptors on mast cells [2, 5, 6]. In cases of re-
exposure to allergen, the specific IgE on the surface of mast
cells catch the allergen, leading to mast cell degranulation and
mediator release, such as histamine, causing chemosis and
ocular itching. Concentrations of many cytokines and
chemokines increase in tears, among them, eotaxin which
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plays a major role in eosinophil and lymphocyte recruitment
[2, 5, 6].
In ocular allergic reactions, some amounts of IgE were
measured in tears of patients suffering from SAC, perennial
allergic conjunctivitis (PAC), vernal (VKC) and atopic kera-
toconjunctivitis (AKC) [7–10].
Eotaxin, also called CC chemokine ligand 11 (CCL11),
was found in basal tears of healthy subjects [11, 12] and was
constitutively expressed in their conjunctiva [13]. A signifi-
cant increase in eotaxin level has been demonstrated in pa-
tients suffering from either SAC during the pollen season or
VKC [14, 15]. Eotaxin concentration in tears of SAC patients
was significantly higher in season than out of season, when
patients were tested at both seasons [14].
Our goal was to analyse the relationship between total IgE
level in tears, eotaxin concentration in tears, the clinical score
of SAC and papilla grade in the upper tarsal conjunctiva. To
our knowledge, this is the first time that both eotaxin and IgE
levels have been concomitantly measured in tears of SAC
patients during the in season.
Materials and methods
Patients and anamnesis
Sixty patients were recruited by the Ocular Immuno-
Infectiology Unit of our hospital in this prospective study
from March 2007 till August 2007 and from March 2008 till
August 2008, which corresponds to the pollen season.
The study was performed in accordance with ethical stan-
dards (Declaration of Helsinki, Human Research Ethics Com-
mittee in Lausanne). All participants gave their informed
consent. A sheet form with questions made it possible to draw
patient medical history and both general and ocular anamne-
sis. Each patient presented with ocular symptoms of SAC,
such as itching, a mandatory symptom, redness, tearing, or
ocular pain and clinical signs, such as mucous discharge,
chemosis, or palpebral papillae. Some patients were suffering
from a known SAC diagnosed at least 1 year ago, i.e., pollen
allergy. The others had not been diagnosed yet as suffering
from SAC at the time of presentation, but were diagnosed as
new SAC cases after their visit to the hospital. Ocular exclu-
sion criteria were PAC, VKC, AKC, parasitic, bacterial or
viral conjunctivitis, glaucoma, rosacea, dry eye syndrome,
and ocular wound. Systemic exclusion criteria were infec-
tions, atopic dermatitis, eczema, nettle rash, and systemic
diseases. Patients were asked to abstain from taking anti-
inflammatory and anti-histaminic drugs. A wash out period
of 10 days was considered for these drugs before the enrol-
ment. None of the subjects wore contact lenses, and none of
them used topical drugs or nasal drops. Given all these criteria,
it was possible to enrol 41 patients for tear collection.
Each individual underwent complete ophthalmic slit-lamp
examination by the same ophthalmologist (MB). Among
retained patients, some were suffering from a known SAC;
the others presented with no known ocular pathology, but their
pathology was finally diagnosed as SAC.
Ocular itching, conjunctival hyperaemia, conjunctival
chemosis, eyelid swelling, and tearing were scored according
to a semi-quantitative scale from 0 to 3. The clinical score was
the sum of the scores for each criterion, where 0 represented
no symptom/sign and 15 the maximum. Papillae were sepa-
rately graded in the upper tarsal conjunctiva by slit-lamp
examination according to a semi-quantitative scale from 0 to
4 based on standard photos [16].
Eotaxin in tears
Around 8 μl of tear samples of each patient was necessary for
analysis. To obtain unstimulated basal tears, the tear samples
were collected with glass microcapillary tubes in the temporal
part of the fornix of the inferior eyelid. No anaesthetic was
used. Tear samples were immediately centrifuged at 4ºC to
remove cells, transferred to new tubes and frozen at –80 °C.
Eotaxin concentrations were measured by a home-made
enzyme-linked immunosorbent assay (ELISA) [14]. A plate
was coated with a capture antibody, the purified mouse anti-
human eotaxin monoclonal antibody 3C7 (Becton Dickinson:
Pharmingen, # 23051D). A serial dilution of recombinant
human eotaxin between 16 and 500 pg/ml and dilutions of
samples were prepared in 0.05 % Tween and 1 % Bovine
Serum Albumin in PBS. After washing and blocking of non-
specific binding, eotaxin dilutions in duplicate and samples
were added. The plate was washed and a detecting antibody,
the biotinylated mouse anti-human eotaxin monoclonal anti-
body 10C11 (BD Pharmingen, # 23252D), was added. The
plate was washed and streptavidin-alkaline phosphatase con-
jugate (BD Pharmingen # 554065) was added. Alkaline phos-
phatase yellow liquid substrate (Sigma, # A3469) was applied,
and the OD was read at 405 nm with a reference filter at
490 nm. Eotaxin concentration in the samples was read from
the standard curve of eotaxin. The limit of the sensitivity of the
test was 60 pg/ml of eotaxin. Samples containing <60 pg/ml
eotaxin were considered eotaxin-negative. Samples ≥60 pg/ml
were considered eotaxin-positive.
Total IgE in tears
After tear collection with the microcapillary, the Lacrytest
(Adiatec SA, Diagnostic and Biotechnologies, Nantes,
France) strip was set in the external third of the inferior lid,
away from the cornea, until a red line appeared in the control
field. The strip was then soaked in the commercial vial for at
least 10min, and removed. Internal control on the strip made it
possible to ensure that the result was valid. Patients presenting
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invalid results were withdrawn from the study. The result was
read in the IgE reactive field where the signal intensity de-
pends on total IgE level. No red line in this field was an
indication that the sample was negative, IgE level being
<2.5 kUI/ml. A red line indicated a positive result, IgE being
≥2.5 kUI/ml. We obtained semi-quantitative IgE concentra-
tions to which we attributed arbitrary units (U): <2.5 kUI/l (=0
arbitrary U), between 2.5 and 10 kUI/l (=5 arbitrary U),
between 10 and 40 kUI/l (=20 arbitrary U) and >40 kUI/l
(=50 arbitrary U).
Statistics
To compare the proportion of patient tears, we drew a contin-
gency table and used the Fisher’s exact test. We compared the
parameters by means of the Wilcoxon-Mann–Whitney test
(Figs. 1, 2, 3 and 4). Values are means ± SEM. Differences
were considered to be statistically significant at p<0.05. The
statistical package Stata, version 12 (StataCorp LP, College
Station, TX, USA) was used.
Results
Thirty patients (30 eyes, Table 1) could be included in this
study for data analysis after exclusion of 11 patients
presenting either invalid IgE results or too few tears to allow
eotaxin measurement. All patients disclosed ocular symptoms
and signs compatible with SAC. None of the patients suffered
from PAC, VKC, AKC, parasitic, bacterial, or viral conjunc-
tivitis. Eight patients were men and 22 women. The mean age
was 40.8±2.9 (SEM) years (range 18–72 years). For 12
patients, we had a record and history of known SAC, diag-
nosed at least 1 year ago. Three patients were also suffering
from asthma (# 5, 11, and 24).
The contingency Table 2 presents patients whose tears
contained zero arbitrary U or a positive value of IgE (5, 20,
or 50 arbitrary U), and no significant amount of eotaxin or a
positive value of eotaxin (≥60 pg/ml). One hundred percent of
patients with tear IgE = 0 showed tear eotaxin = 0, whereas
among patients with a positive value of IgE, 79 % patients
showed a positive value of eotaxin (Fisher’s exact test, two-
tailed; p<0.001).
In Fig. 1, mean eotaxin concentration reached 29±8 pg/ml
(under the threshold of test sensitivity) (range 0–60 pg/ml) in
tears without IgE and 641±154 pg/ml (0–2,132 pg/ml) in tears
where IgE was positive (p=0.001).
Tear IgE value was 5.3±3.5 arbitrary U in the 15 patients
whose eotaxin concentration was under the threshold of sen-
sitivity (Fig. 2), and 21±4.3 arbitrary U in the 15 patients
whose tears contained a positive amount of eotaxin. The










Fig. 1 Tear eotaxin concentration
and absence (0) or presence of
IgE in tears. Bars = means









Fig. 2 Total tear IgE
concentration and absence (0) or










Fig. 3 Eotaxin concentration in
tears of patients presenting signs
and symptoms of SAC. Some
patients had a history of SAC
(known); for the others, SAC was
newly diagnosed following the
visit at the hospital (new).
Bars = means
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Eotaxin concentrations were compared in tears of patients
with a history of SAC and patients who had no history of
SAC, but were newly diagnosed as suffering from SAC,
according to symptoms and signs and after excluding other
allergies (Fig. 3). Eotaxin concentration reached 127±47 pg/
ml (0–758 pg/ml) in patients with newly diagnosed SAC, and
852±218 pg/ml (0–2,132 pg/ml) in tears of patients where
SACwas already known. The difference between both groups
is statistically significant (p=0.008).
Concentrations of IgE were not significantly different in
patients with a newly diagnosed SAC and those with SAC
history (not shown) (p=0.947). Similarly, the clinical score
was not significantly different in both groups of patients
(Fig. 4) (p=0.797).
Patients which had no IgE in their tears showed a lower
conjunctival papilla grade than patients whose tears contained
some IgE (Fig. 5) (p=0.0318). On the other hand, there was
no correlation between papilla grade and eotaxin presence in
tears (not shown) (p=0.2194).
Discussion
We focused on patients suffering from SAC during the pollen
season. SAC mechanism was demonstrated to be different
from the mechanisms of more severe allergy cases such as
VKC and AKC [3]. For instance, SAC induces penetration of
conjunctiva by mast cells and later on neutrophils and
eosinophils, whereas VKC and AKC mainly involve T cells
and eosinophils [3].
We wanted to specifically study the relation between IgE
and eotaxin in tears of patients suffering from SAC during the
in season. The relation between IgE and eotaxin has been
investigated in plasma of asthmatic patients [17]. Plasma
eotaxin values correlated with the total IgE values in asthmatic
and non-asthmatic patients, suggesting that eotaxin may play a
role in asthma severity [17]. To our knowledge, such compar-
ison was not studied yet in ocular pathologies.
Detection and quantification of IgE in serum is the standard
method for diagnosis of seasonal allergy [10]. Some authors
have demonstrated that total tear IgE was correlated to serum
IgE [7, 10, 18]. On the other hand, the largest contributor to
the severity of SAC is the locally produced IgE [19, 20].
Measurement of IgE in tears may be therefore a quicker way
to diagnose SAC thanmeasurement of the serum-specific IgE.
A few tests exist to measure total IgE in tears. A test in
Japan made it possible to detect high levels of total IgE mean
in tears of SAC and PAC patients in comparison to normal
patients [7]. A Phadezym–PRIST test was able to show that
tears of SAC patients contain more IgE than control tears [19].
The Allerwatch test was used by Japanese groups; tears of an
autumnal allergic group of patients contained a higher value of
IgE than tears of a control group [21].
For detection of specific IgE in tears, a Japanese group has
been evaluating a commercial immunochromatographic test









Fig. 4 Clinical score of allergic
conjunctivitis in patients
presenting signs and symptoms of
SAC. Some patients had a history
of SAC (known); for the others,
SAC was newly diagnosed
following the visit at the hospital
(new). Bars = means, p=0.797
Graefes Arch Clin Exp Ophthalmol (2014) 252:1359–1367 1363
tears [22]. For instance, Cedar pollen-specific IgE were sig-
nificantly higher in tears of allergic conjunctivitis patients than
in control subjects.
We chose the Lacrytest since it is an easy and rapid method
to estimate total IgE levels in a very small volume of tears. The
Lacrytest was previously used in a clinical study on subjects
presenting, or not, signs of ocular allergy [23]. The test
showed very good results, with a sensitivity of 93.8 % and a
specificity of 89.7 %. In another study, if Lacrytest specificity
reached 100 % [24], sensitivity was only 20 %. This was
probably due to the fact that some patients enrolled in that
study did not show ocular symptoms and signs of allergic
conjunctivitis at the moment of the visit. Indeed, when pa-
tients were submitted to conjunctival provocation test with the
suspected allergen, sensitivity raised to 66.7 % [24].
The presence of IgE in tears of patients affected by SAC
has already been demonstrated [7, 19]. However, there were
always a few patients presenting SAC but where no IgE could
be revealed in their tears [19, 25]. For instance, presence of
IgE in tears was revealed in 23 out of 28 SAC patients [6].
Why, in our cohort of 30 patients, did only 19 demonstrate
Table 1 Patient characteristics of
the prospective study. Patients
presented seasonal allergic con-
junctivitis (SAC) symptoms. For
some patients, SAC had already
been diagnosed (+); for the others,
SAC was unknown at time of
presentation (−)
Patient # Age Gender History of SAC Clinical score Papilla grade
1 49 F – 6 1
2 33 F + 10 2
3 49 F – 5 1
4 54 F + 4 2
5 36 F + 5 2
6 47 F + 9 2
7 54 F + 9 2
8 44 F + 7 2
9 39 M – 7 2
10 18 M + 3 3
11 23 F + 8 2
12 18 M – 6 2
13 27 F – 7 2
14 61 M – 5 1
15 72 M – 6 1
16 24 F + 5 1
17 62 F – 9 3
18 35 F – 7 3
19 23 F – 5 1
20 40 F – 8 0
21 18 M – 8 2
22 60 M – 11 3
23 18 M – 15 3
24 24 F – 5 2
25 55 F + 10 2
26 60 F – 10 2
27 35 F – 7 2
28 55 F + 8 0
29 31 F – 5 1
30 59 F + 8 2
Table 2 Frequencies of patients whose tears contain, or do not contain
IgE and eotaxin. Number of patients (% of patients). Fisher’s exact test,
two-tailed: p<0.001
IgE value Eotaxin value
0 Positive Total
0 11 0 11
100 % 0 % 100 %
Positive 4 15 19
21 % 79 % 100 %
Total 15 15 30
50 % 50 % 100 %
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significant amounts of total tear IgE? It may be that, by
chance, we recruited patients with lower SAC symptoms than
in other studies. Therefore, their IgE levels were too low to be
revealed by our test. On the other hand, we observed a fair
interindividual variance in tear IgE values, phenomenon
which was already described [18, 19].
In the present study, we detected 127±47 pg/ml of eotaxin
in tears of patients whose pathology was newly described as
SAC, and 852±218 pg/ml in tears of patients with a history of
SAC. These values are comparable to those reported in tears
of SAC patients by Leonardi [15].
Eotaxin has been detected in tears of patients presenting
various allergic reactions [15, 26, 27]. This chemokine was
also revealed in healthy patients, but to a lesser extent [11].
Eotaxin values in our study are higher than in some other
studies. This could be explained by the use of different con-
ditions during the detecting method. An important study com-
pared the amounts of some cytokines and chemokines detect-
ed in human tears using the cytometric bead-based assay in
different conditions [12]: with or without sample dilution
before storage, with or without detergent, with or without
bovine serum albumin. In the same initial sample, the authors
measured eotaxin values ranging from 170 to 750 pg/ml after
applying eight different conditions [12].
We showed, to some extent, a concomitant presence of
total tear IgE and tear eotaxin in SAC patients. The absence
of IgE in tears necessarily implies the absence of significant
amounts of eotaxin. But the presence of tear IgE implies the
presence of eotaxin in only 79 % of patients.
In our study, there was no difference in total tear IgE levels
between patients with a known SAC and patients with a newly
diagnosed SAC. Moreover, the two groups of patients did not
differ with regard to their clinical score mean. In contrast,
patients with a known SAC exhibited significantly higher
amounts of tear eotaxin than patients with a newly diagnosed
SAC. Our findings confirm that IgE and eotaxin, if principal
actors in the pathology of SAC, act separately along the
allergic reaction [1].
Both IgE and eotaxin intervene at different phases of the
pathogenesis of SAC. During the phase of sensitization, B
lymphocytes of the conjunctiva produce IgE against the aller-
gen, which will link to mast cells. During the challenge phase,
the allergen binds with specific IgE on the conjunctival mast
cells, leading to mast cell degranulation and mediator release,
characteristic of the acute phase allergic reaction. Eotaxin is a
major contributor which induces inflammatory cell invasion,
driving the late and chronic phase of allergy [2, 3]. This
chemokine specifically stimulates eosinophils chemotaxis
and aggregation through the chemokine receptor 3 (CCR3),
which is expressed in high numbers on eosinophils [28, 29].
Eotaxin induces chemotaxis of other cells wearing CCR3, for
instance lymphocytes and basophils [27]. But this CC chemo-
kine also plays a role in mast cell priming, since it provides a












Fig. 5 Conjunctival papilla grade
and absence (0) or presence of
IgE in tears. Bars = means
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Extensive studies have proved that experimental allergic
conjunctivitis is ablated in mice deficient in eotaxin [1, 3].
After induction of allergic inflammation in the conjunctiva
of these mutant mice, the authors counted normal numbers
of tissue mast cells in conjunctiva, and measured normal
levels of IgE. However, these eotaxin-deficient mice
showed a significant impairment of mast cell degranulation
and a suppression of clinical symptoms in the acute phase
reaction [1]. As mast cell degranulation does not depend
on eotaxin, the authors hypothesized that this chemokine
might provide a co-stimulatory signal, and that CCR3
plays a major role in activation of mature connective
tissue-type mast cells in ocular tissue. Indeed, when
CCR3 was blocked, allergen-mediated hypersensitivity re-
action and IgE-mediated mast cell degranulation were
suppressed [1]. Therefore, the eotaxin/CCR3 axis is the
main control of mast-cell-mediated allergy.
The role of CCR3 in allergic conjunctivitis has been
previously demonstrated in mice subjected to allergic
sensitization [31]. Anti-CCR3 suppressed both clinical
signs of allergic inflammation and mast cell degranula-
tion, but could not reduce the serum levels of specific
IgE in mice [31].
Presence of conjunctival papillae is characteristic of AKC,
VKC, and contact lens wear [13, 16, 32, 33]. We were able to
demonstrate that our SAC patients had a low to mod-
erate conjunctival papilla grade during the in season.
We observed that patients with a positive amount of
IgE in their tears were characterized by a higher conjunctival
papilla grade than patients with no IgE. A mild papillary
hypertrophy was previously observed in the upper tarsal
conjunctiva of patients suffering from seasonal allergic
rhinoconjunctivitis [4].
In conclusion, we investigated a cohort of patients suffer-
ing from SAC during the pollen season.We are aware of some
limitations of interpretation of our data; Lacrytest is a semi-
quantitative test with an arbitrary endpoint to determine pos-
itive or negative results, and the detecting test for eotaxin has a
sensitivity threshold of 60 pg/ml. However, the data suggest
that when patient tears contained IgE, they were often likely to
contain eotaxin too. Patients with a history of SAC
were compared to patients with a newly diagnosed
SAC. Both groups of patients demonstrated the same
level of total tear IgE in mean, and the same clinical
score. In contrast, patients with a known SAC had a signifi-
cantly higher level of eotaxin in their tears than patients with a
newly SAC. This confirms that, if IgE and eotaxin are princi-
pal actors in IgE-mediated SAC, they contribute separately to
the reaction.
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